{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05776563",
            "orgStudyIdInfo": {
                "id": "2000034676"
            },
            "secondaryIdInfos": [
                {
                    "id": "1K23DK132517-01A1",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/1K23DK132517-01A1"
                }
            ],
            "organization": {
                "fullName": "Yale University",
                "class": "OTHER"
            },
            "briefTitle": "Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)",
            "officialTitle": "Reversibility of Brain Glucose Transport and Metabolism in T2DM",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "reversibility-of-brain-glucose-transport-in-type-diabetes-mellitus"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-19",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-05-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-05-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-06",
            "studyFirstSubmitQcDate": "2023-03-08",
            "studyFirstPostDateStruct": {
                "date": "2023-03-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Yale University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to learn about the effects of high blood glucose levels in the brain and assess if the changes seen in individuals with poorly control T2DM can be reversed with good glucose control.\n\nThe main question\\[s\\] it aims to answer are:\n\n* To determine, whether abnormalities in brain glucose transport seen in individuals with uncontrolled diabetes, can be improved with better glucose control.\n* Assess which factors, (duration of diabetes mellitus (DM) and glycemic control) contribute to changes in glucose transport\n\nParticipants will have:\n\n* A screening visit\n* placement of a continuous glucose monitor (CGM) 2 weeks before the first magnetic resonance spectroscopy (MRS) at week 0\n* Additional visits/phone calls for intensification of diabetes management and nutrition visits\n* Second magnetic resonance spectroscopy (MRS) at week 12"
        },
        "conditionsModule": {
            "conditions": [
                "Diabetes Mellitus, Type 2"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 34,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Brain Glucose Levels in Participants with Type 2 Diabetes",
                    "type": "OTHER",
                    "description": "Intensification of diabetes management",
                    "interventionNames": [
                        "Other: Magnetic Resonance Spectroscopy Imaging (MRSI)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Magnetic Resonance Spectroscopy Imaging (MRSI)",
                    "description": "baseline 1HMRSI imaging study, then will undergo intensification of their diabetes management for a period of 12-week and at the end of the intervention they will undergo 1H MRSI scanning to measure intracerebral and plasma glucose levels at euglycemia and following 2 hours of hyperglycemia using the clamp technique (target glucose 220 mg/dl) in the occipital region",
                    "armGroupLabels": [
                        "Brain Glucose Levels in Participants with Type 2 Diabetes"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in magnetic resonance spectroscopy (MRS) to assess brain glucose changes",
                    "description": "Brain glucose changes in the occipital lobe will be measured by 1H MRS following hyperglycemic clamp in T2DM individuals at week 0 and at week 12. An improvement in glucose control indicates an increase in brain glucose levels at week 12 compared to historical control.",
                    "timeFrame": "baseline and week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 18-60\n* medical history for Type 2 diabetes\n* HbA1c \\> 7.5%, BMI \u226518 kg/m2\n* Be willing to adhere to the intensification of their diabetes regimen\n\nExclusion Criteria:\n\n* Creatinine \\> 1.5 mg/dL\n* Hgb \\< 10 mg/dL, hematocrit of 37 % for males participants and 33 % for female participants\n* ALT \\>3 x ULN\n* untreated thyroid disease,\n* uncontrolled hypertension\n* known neurological disorders\n* untreated psychiatric disorders\n* malignancy\n* bleeding disorders\n* current or recent steroid use in last 3 months\n* illicit drug use\n* for women: pregnancy, actively seeking pregnancy, or breastfeeding\n* inability to enter MRI/MRS (as per standard MRI safety guidelines).",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "60 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Elizabeth Sanchez Rangel, MD",
                    "role": "CONTACT",
                    "phone": "203-785-6430",
                    "email": "elizabeth.sanchezrangel@yale.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Elizabeth Sanchez Rangel, MD",
                    "affiliation": "Yale University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Yale New Haven Hospital (YNHH) Research Unit (HRU)",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06520",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000003924",
                    "term": "Diabetes Mellitus, Type 2"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7119",
                    "name": "Diabetes Mellitus, Type 2",
                    "asFound": "Diabetes Mellitus, Type 2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "asFound": "Diabetes Mellitus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}